Company Description
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.
The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals.
The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019.
Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
| Country | United States |
| IPO Date | May 20, 1998 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Dr. Thomas W. Burnell Ph.D. |
Contact Details
Address: Waterview Plaza, Suite 310, 2001 Route 46 Parsippany, New Jersey 07054 United States | |
| Phone | 412-224-6100 |
| Website | interpace.com |
Stock Details
| Ticker Symbol | IDXG |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001054102 |
| CUSIP Number | 46062X303 |
| ISIN Number | US46062X3035 |
| Employer ID | 22-2919486 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas W. Burnell Ph.D. | President, Chief Executive Officer and Chairman |
| Christopher McCarthy | Chief Financial Officer |
| Dr. Sydney D. Finkelstein | Chief Scientific Officer |
| Jody Campbell | Chief Revenue Officer |
| Dr. Nicole Massoll M.D. | Chief Medical Officer |
| Patrick Kane | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 12, 2023 | 8-K | Current Report |
| Nov 16, 2023 | 8-K | Current Report |
| Nov 8, 2023 | 8-K | Current Report |
| Nov 8, 2023 | 10-Q | Quarterly Report |
| Oct 27, 2023 | 8-K | Current Report |
| Sep 22, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 22, 2023 | DEF 14A | Other definitive proxy statements |